Hypoactive Sexual Desire Disorder Treatment Market Outlook, Size, Demand, Top Companies and Forecast Report 2023-2028
The latest report published by IMARC Group, titled “Hypoactive Sexual Desire Disorder Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the market share. The report also includes competitor and regional analysis, and contemporary advancements in the market.
Market Overview:
The global hypoactive sexual desire disorder treatment market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 4.8% during 2023-2028.
Hypoactive sexual desire disorder (HSDD) represents a medical condition with low libido or sexual desire in women. The sexual dysfunction in HSDD is mainly associated with hypofunctional excitation and hyperfunction inhibition regulated by neuromodulators in the brain. Several physical conditions are also related to this condition, including depression, diabetes, urinary incontinence, anxiety, menopause, multiple sclerosis, etc. HSDD treatment largely includes psychotherapy or pharmacotherapy. Psychotherapy utilizes cognitive behavioral treatment that offers counseling sessions with a sex therapist, whereas pharmacotherapy comprises medicine with various drugs, such as Bupropion, Testosterone, Buspirone, Flibanserin, etc. As a result, HSDD treatment finds widespread applications in hospitals and clinics.
Request a Free PDF Sample of the Report: https://www.imarcgroup.com/hypoactive-sexual-desire-disorder-treatment-market/requestsample
Market Trends and Drivers:
The rising working women population and their hectic work schedules often result in low libido conditions, thereby propelling the demand for this therapy, which is among the primary factors driving the hypoactive sexual desire disorder treatment market. Besides this, the high prevalence of several lifestyle ailments, including anxiety, stress, depression, prolonged fatigue, irregular menstruation, etc., is further augmenting the market growth.
The growing popularity of the PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) in the initial screening of HSDD is also catalyzing the global market. Apart from this, the increasing geriatric women population, premature menopause, and low self-esteem toward physical appearance are acting as significant growth-inducing factors. The reduced stigma associated with this treatment and the growing awareness towards disease diagnosis and effective therapy are also stimulating the market growth. Furthermore, the introduction of ‘Vyleesi’ that activates melanocortin receptors in women for improving this condition, faster drug approvals, and the inflating investments in new medicine development activities are expected to bolster the hypoactive sexual desire disorder treatment market in the coming years.
Competitive Landscape With Key Players:
The competitive landscape of the hypoactive sexual desire disorder treatment market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- Allergan Plc
- AMAG Pharmaceuticals, Inc.
- Emotional Brain BV
- Endoceutics, Inc.
- GlaxoSmithKline Plc
- Ovoca Bio Plc
- Pivot Pharmaceuticals, Inc.
- Palatin Technologies, Inc.
- S1 Biopharma, Inc.
- Sprout Pharmaceuticals, Inc.
Key Market Segmentation:
The report has segmented the global hypoactive sexual desire disorder treatment market based on therapy, distribution channel, application and region.
Breakup by Therapy:
- Buspirone
- Bupropion
- Testosterone
- Flibanserin
- Bremelanotide
- Cognitive Behavior Therapy
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Application:
- Hospitals
- Clinics
- Others
Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St
Brooklyn, NY 11249, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian